Certara (CERT) had its "equal weight" rating reaffirmed by Barclays PLC. They now have a $8.00 price target on the stock.
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib [Yahoo! Finance]
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Assessing Certara (CERT) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Certara (CERT) had its price target lowered by Barclays PLC from $13.00 to $8.00. They now have an "overweight" rating on the stock.